Plecanatide (Trulance®): Follow up Approval for IBS-C, a second indication, in USA

Plecanatide (Trulance®): Follow up Approval for IBS-C, a second indication, in USA

In January 2018, plecanatide (Trulance®), developed by Synergy Pharmaceuticals, received approval for the treatment of adult patients with irritable bowel syndrome with constipation (IBS-C).[1] This is the second indication for the agent and comes a year after its first global approval in the US for the treatment of adults with chronic idiopathic constipation (CIC).[2] Continue reading “Plecanatide (Trulance®): Follow up Approval for IBS-C, a second indication, in USA”

Plecanatide (Trulance™): First Global Approval –new treatment option for gastrointestinal disorders

Plecanatide (Trulance™): First Global Approval –new treatment option for gastrointestinal disorders

The recent first global approval of plecanatide has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight.

Late January 2017, plecanatide (Trulance™), developed by Synergy Pharmaceuticals, received its first global approval in the USA for the treatment of adult patients with chronic idiopathic constipation (CIC). Plecanatide is an oral guanylate cyclase-C (GC-C) agonist that regulates ion and fluid transport in the gastrointestinal tract. Continue reading “Plecanatide (Trulance™): First Global Approval –new treatment option for gastrointestinal disorders”